RxDoctor Payments Data

Christina Escobar, MD

Urogynecology and Reconstructive Pelvic Surgery · New York, NYNPI 1346651890

Payments from drug & device makers

What this record shows

This record is dominated by grants: $10,000 of the $11,661 with a category attached, or 85.8%. Medtronic accounts for 91.5% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2021 at $10,086 and has fallen 98.8% since, to $125 in 2025.

$11,661in general payments, 2019–2025

Across 40 payments — averaging $291.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$11K
  • Boston Scientific$283
  • AbbVie$191
  • Johnson & Johnson$75
  • ABC Home Medical Supply, Inc.$74
  • Coopersurgical, Inc.$69
  • plus $301 from 9 others

What the payments were for

  • Grants$10,00086%
  • Food & beverage$1,61214%
  • Education$480%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,661 in reported general payments places this provider in the 85th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.

See all urogynecology and reconstructive pelvic surgery providers in New York

Medicare billing

Part B allowed, 2024
$47,782
Medicare patients
111
Services billed
1,639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron48$34,814
MyrbetriqMirabegron35$21,533
EstringEstradiol21$10,636
Estradiol104$6,249
ImvexxyEstradiol12$5,211
Solifenacin Succinate28$2,921
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst21$331
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$51$21,53335 claims
PfizerEstring$42$10,63621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.

Other urogynecology and reconstructive pelvic surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →